The management of mild to severe acute ulcerative colitis

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2004-09-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2004.02056.xPMID 15352901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting outcome in severe ulcerative colitis.

  2004cited by this paper
• Ciclosporin and refractory colitis.

  2003cited by this paper
• Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study.

  2003cited by this paper
• Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

  2003cited by this paper
• RDP-58: novel and effective therapy for ulcerative colitis. results of parallel, prospective, placebo-controlled trials

  2003cited by this paper
• Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.

  2003cited by this paper
• Medical treatment of severe ulcerative colitis

  2002cited by this paper
• Outcome of in-patient management of severe colitis: A BSG IBD clinical network survey

  2002cited by this paper
• Review article: medical treatment of severe ulcerative colitis.

  2002cited by this paper
• Audit of the management of severe ulcerative colitis in a DGH

  2001cited by this paper
• Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.

  2001cited by this paper
• Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.

  2000cited by this paper
• A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis

  2000cited by this paper
• Prediction of Treatment Refractoriness in Ulcerative Colitis and Crohn's Disease—Do We Have Reliable Markers?

  2000cited by this paper
• Efficacy and Efficiency of Oral Microemulsion Cyclosporin Versus Intravenous and Soft Gelatin Capsule Cyclosporin in the Treatment of Severe Steroid‐Refractory Ulcerative Colitis: An Open‐Label Retrospective Trial

  1998cited by this paper
• Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis

  1998cited by this paper
• A simple clinical colitis activity index

  1998cited by this paper
• Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis

  1997cited by this paper
• Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

  1997cited by this paper
• A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.

  1997cited by this paper
• Predicting outcome in severe ulcerative colitis.

  1996cited by this paper
• Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.

  1994cited by this paper
• Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis.

  1993cited by this paper
• Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

  1987cited by this paper
• Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.

  1986cited by this paper
• Intensive intravenous regimen for severe attacks of ulcerative colitis.

  1974cited by this paper
• Noradrenaline in Acute Peripheral Circulatory Failure

  1956cited by this paper
• FINAL REPORT ON A THERAPEUTIC TRIAL

  1955cited by this paper
• WHAT IS ULCERATIVE COLITIS

  1953cited by this paper
• ULCERATIVE COLITIS COURSE AND PROGNOSIS

  1950cited by this paper

• Chitosan functionalized Mn3O4 nanoparticles counteracts ulcerative colitis in mice through modulation of cellular redox state

  2023cites this paper
• Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

  2023cites this paper
• Regulation of the Intestinal Extra-Adrenal Steroidogenic Pathway Component LRH-1 by Glucocorticoids in Ulcerative Colitis

  2022cites this paper
• Evaluation of Protective Effects of Hydroalcoholic Extract Obtained from Cucurbita moschata Skin in Animal Model of Ulcerative Colitis

  2022cites this paper
• Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: A meta-analysis.

  2021cites this paper
• Monitoring Of Severe Crohn's Colitis Treated With Intravenous Corticosteroids By C-Reactive Protein: Results Of A Prospective Study

  2020cites this paper
• Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial

  2019cites this paper
• Efficacy and safety of a standardized extract from Achillea wilhelmsii C. Koch in patients with ulcerative colitis: A randomized double blind placebo-controlled clinical trial.

  2019cites this paper
• Protective and Therapeutic Effect of Oleoresin of Pistacia atlantica in Acetic Acid-induced Colitis in Rat

  2019cites this paper
• Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Primer for Internists.

  2018cites this paper
• Healthcare professionals’ views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial

  2017cites this paper
• EPA- and DHA-derived resolvins' actions in inflammatory bowel disease.

  2016cites this paper
• Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).

  2016cites this paper
• Neutrophil-to-lymphocyte ratio in inflammatory bowel disease - as a new predictor of disease severity.

  2015cites this paper
• Corticosteroid therapy in ulcerative colitis: Clinical response and predictors.

  2015cites this paper
• Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis

  2015cites this paper
• Clinical audit: recent practice in caring for patients with acute severe colitis compared with published guidelines – is there a problem?

  2013cites this paper
• What is the importance of infliximab and cyclosporine in the treatment of corticosteroid-refractory severe ulcerative colitis?

  2012cites this paper
• Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis.

  2012cites this paper
• Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity.

  2012cites this paper
• Oral high dose Beclomethasone dipropionate for treatment of active ulcerative colitis

  2012cites this paper
• The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.

  2011cites this paper
• Topische Therapie bei Colitis ulcerosa

  2011influential citation
• Oral Beclomethasone Dipropionate as an Alternative to Systemic Steroids in Mild to Moderate Ulcerative Colitis Not Responding to Aminosalicylates

  2010cites this paper
• Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis.

  2010cites this paper
• An overlooked indicator of disease activity in ulcerative colitis: Mean platelet volume

  2009cites this paper
• Severe ulcerative colitis: present medical treatment strategies

  2008cites this paper
• The cost‐utility of high dose oral mesalazine for moderately active ulcerative colitis

  2008cites this paper
• Review article: 5‐aminosalicylate formulations for the treatment of ulcerative colitis – methods of comparing release rates and delivery of 5‐aminosalicylate to the colonic mucosa

  2008cites this paper
• The Natural Course of Ulcerative Colitis : A European Population-Based Study

  2007cites this paper
• Clinical manifestations and outcomes in severe ulcerative colitis

  2007cites this paper
• Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis.

  2007cites this paper
• Errores frecuentes en el manejo del paciente grave con enfermedad inflamatoria intestinal

  2007cites this paper
• [Common errors in the management of the seriously ill patient with inflammatory bowel disease].

  2007cites this paper
• Multidrug resistance gene‐1 polymorphisms and resistance to cyclosporine a in patients with steroid resistant ulcerative colitis

  2007cites this paper
• Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.

  2007cites this paper
• Management of inflammatory bowel diseases in Eastern Europe

  2006cites this paper
• Systematic review: infliximab therapy in ulcerative colitis

  2006cites this paper
• Combined oral and topical mesalazine treatment for extensive ulcerative colitis

  2006cites this paper